1. Diabetes Care. 2020 May;43(5):940-947. doi: 10.2337/dc19-1769. Epub 2020 Mar
5.

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body 
Weight.

Sivitz WI(1), Phillips LS(2)(3), Wexler DJ(4), Fortmann SP(5), Camp AW(6), 
Tiktin M(7), Perez M(6), Craig J(8), Hollander PA(9), Cherrington A(10), Aroda 
VR(11), Tan MH(12), Krakoff J(13), Rasouli N(14), Butera NM(15), Younes N(15); 
GRADE Research Group.

Collaborators: Crandall JP, Diane McKee M, Brown-Friday J, Xhori E, 
Ballentine-Cargill K, Duran S, Lukin J, Beringher S, Gonzalez de la Torre S, 
Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Stephanie Raines T, Costello 
J, Gullett C, Maher-Albertelli M, Morehead F, Mungara R, Person S, Savoye L, 
Sibymon M, Tanukonda S, Ann White C, Holloway L, Adams C, Ross A, 
Balasubramanyam A, Gonzalez E, Wright C, Hollander P, Roe E, Uy A, Burt P, 
Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, 
Tiktin M, Cramer B, Iacoboni J, Kononets MV, Kulow T, Newman C, Stancil KA, 
Sanders C, Tucker L, Werner A, Krol A, McPhee G, Patel C, Colosimo L, Goland R, 
Pring J, Kringas P, Tejada J, Hausheer C, Schneier H, Gumpel K, Kirpitch A, 
Green JB, AbouAssi H, Chatterjee R, Feinglos MN, English Jones J, Khan SA, 
Kimpel JB, Zimmer RP, Furst M, Satterwhite BM, Thacker CR, Evans Kreider K, 
Mather KJ, Lteif A, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Howard D, 
Aguillar D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt 
J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Passi R, Kleeberger K, 
Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Anne 
Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow 
S, Bays K, Cook J, Gluth J, Sasaki D, Schell K, Criscola J, Friason C, Jones S, 
Nazarov S, Barzilay J, Rassouli N, Puttnam R, Curtis M, Stokes K, Hollis B, 
Sanders-Jones C, Nelson R, El-Haqq Z, Kolli A, Tran T, Wexler D, Mary L, Meigs 
J, Dushkin A, Rocchio G, Chambers B, Yepes M, Steiner B, Dulin H, Cayford M, 
DeManbey A, Gurry L, Hillard M, Martin K, Stevens C, Thangthaeng N, Kochis R, 
Raymond E, Ripley V, Park J, Aroda V, Ghazi A, Loveland A, Hurtado M, Kuhn A, 
Mofor F, Florez HJ, Valencia WM, Marks J, Oropesa-Gonzalez L, Riccio Veliz AK, 
Nieto-Martinez R, Gutt M, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague 
C, Yamashita D, Cady N, Kirchhoff P, Rivera-Eschright N, Adducci J, Gomez BM, 
Goncharova A, Hox SH, Petrovitch H, Matwichyna M, Jenkins V, Bermudez NO, Ishii 
RR, Hsia DS, Cefalu WT, Greenway FL, Waguespack C, King E, Haynes N, Thomassie 
A, Bourgeois B, Hazlett C, Henry R, Mudaliar S, Boeder S, Pettus J, Diaz E, 
DeLue C, Castro E, Hernandez S, Krakoff J, Curtis JM, Killean T, Joshevama E, 
Diaz E, Martin D, Karshner T, Albu J, Pi-Sunyer FX, Frances S, Maggio C, Ellis 
E, Bastawrose J, Gong X, Ann Banerji M, August P, Lorber D, Brown NM, Josephson 
DH, Thomas LL, Tsovian M, Cherian A, Jacobson MH, Mishko MM, Kirkman MS, Bergamo 
K, Buse JB, Dostou J, Young L, Goley A, Kerr J, Largay JF, Guarda S, Cuffee J, 
Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, 
Fuller G, Garvey WT, Cherrington A, Golson D, Griffith O, Catherine Robertson M, 
Agne A, McCullars S, Cohen RM, Craig J, Kersey K, Rogge MC, Wilson C, Burton K, 
Lipp S, Vonder Meulen MB, Rasouli N, Schroeder E, Steiner S, Baker C, 
Underkofler C, Douglass S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, 
Herman WH, Pop-Busui R, Tan MH, Martin C, Waltje A, Goodhall L, Eggleston R, Kuo 
S, Bule S, Kessler N, LaSalle E, Seaquist ER, Bantle A, Kumar A, Redmon B, 
Bantle J, Harindhanavudhi T, Coe M, Mech M, Taddese A, Lesne L, Smith S, Desouza 
C, Kuechenmeister L, Shivaswamy V, Laura Morales A, Rodriguez MG, Seipel K, 
Alfred A, Eggert J, Lord G, Taylor W, Tillson R, Schade DS, Adolphe A, Burge M, 
Duran-Valdez E, Martinez J, Doris Hernandez McGinnis, Pucchetti B, Scripsick E, 
DeFronzo RA, Cersosimo E, Abdul-Ghani M, Triplitt C, Verastiqui H, Irene Garza 
R, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Fan Jordan L, Sao S, Morton 
L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Brian Kraymer R, 
Sturgess D, Utzschneider KM, Kahn SE, Alarcon-Casas Wright L, Boyko EJ, Tsai EC, 
Trence DL, Fattaleh BN, Montgomery BK, Atkinson KM, Concepcion T, Kozedub A, 
Moak C, Rhothisen S, Elasy TA, Martin S, Shackelford L, Goidel R, Hinkle N, 
Lipps Hogan J, Lovell C, Myers J, McGill JB, Salam M, Kissel S, Schweiger T, 
Recklein C, Tamborlane W, Gatcomb P, Camp A, Gulanski B, Inzucchi S, Pham K, 
Alguard M, Lessard K, Perez M, Magenheimer E, Montoza A, Nathan DM, Lachin J, 
Buse JB, Kahn SE, Krause-Steinrauf H, Larkin M, Tiktin M, Wexler D, Burch HB, 
Linder B, Bremer A, Lachin J, Krause-Steinrauf H, Younes N, Backman M, Bebu I, 
Buys CJ, Fagan Murphy A, Gao Y, Gramzinski M, Hall S, Legowski E, Arey A, 
Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, 
Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, 
Scrymgeour A, Soliman EZ, Zhang ZM, Campbell C, Hu J, Keasler L, Hensley S, Li 
Y, Herman W, Martin C, Waltje A, Kuo S, Mihalcea R, Perez-Rosas V, Prosser L, 
Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Burch HB, Bremer A, 
Linder B, Fradkin J, Groessl E, Chong H, Hillery N, Abdouch I, Brantley P, 
Broyles FE, Canaris G, Copeland P, Craine JJ, Fein WL, Lee MS, Meiners R, 
Meiners V, O'Neal H, Park JE, Sledge E Jr, Steppel-Resnick J, Turchin A, 
Brooks-Worrell B, Hampe CS, Newgard CB, Palmer JP, Shojaie A, Higgins J, Fischer 
L, Golden S, Gonzalez J, Naik A, Walker E, Doner Lotenberg L, Gallivan JM, Lim 
J, Tuncer DM, Behringer-Massera S.

Author information:
(1)University of Iowa, Iowa City, IA grademail@bsc.gwu.edu.
(2)Atlanta VA Medical Center, Decatur, GA.
(3)Emory University School of Medicine, Atlanta, GA.
(4)Diabetes Clinical Research Center, Massachusetts General Hospital, Harvard 
Medical School, Boston, MA.
(5)Kaiser Permanente Northwest, Portland, OR.
(6)Fair Haven Community Health Care, New Haven, CT.
(7)Case Western Reserve University, Cleveland, OH.
(8)University of Cincinnati, Cincinnati, OH.
(9)Baylor Research Institute, Dallas, TX.
(10)University of Alabama, Birmingham, AL.
(11)MedStar Health Research Institute, Hyattsville, MD.
(12)University of Michigan, Ann Arbor, MI.
(13)Southwestern American Indian Center, Phoenix, AZ.
(14)University of Colorado, Denver, CO.
(15)Department of Biostatistics and Bioinformatics, The Biostatistics Center, 
Milken Institute School of Public Health, The George Washington University, 
Rockville, MD.

OBJECTIVE: We evaluated the effect of optimizing metformin dosing on glycemia 
and body weight in type 2 diabetes.
RESEARCH DESIGN AND METHODS: This was a prespecified analysis of 6,823 
participants in the Glycemia Reduction Approaches in Diabetes: A Comparative 
Effectiveness Study (GRADE) taking metformin as the sole glucose-lowering drug 
who completed a 4- to 14-week (mean ± SD 7.9 ± 2.4) run-in in which metformin 
was adjusted to 2,000 mg/day or a maximally tolerated lower dose. Participants 
had type 2 diabetes for <10 years and an HbA1c ≥6.8% (51 mmol/mol) while taking 
≥500 mg of metformin/day. Participants also received diet and exercise 
counseling. The primary outcome was the change in HbA1c during run-in.
RESULTS: Adjusted for duration of run-in, the mean ± SD change in HbA1c was 
-0.65 ± 0.02% (-7.1 ± 0.2 mmol/mol) when the dose was increased by ≥1,000 
mg/day, -0.48 ± 0.02% (-5.2 ± 0.2 mmol/mol) when the dose was unchanged, and 
-0.23 ± 0.07% (-2.5 ± 0.8 mmol/mol) when the dose was decreased (n = 2,169, 
3,548, and 192, respectively). Higher HbA1c at entry predicted greater reduction 
in HbA1c (P < 0.001) in univariate and multivariate analyses. Weight loss 
adjusted for duration of run-in averaged 0.91 ± 0.05 kg in participants who 
increased metformin by ≥1,000 mg/day (n = 1,894).
CONCLUSIONS: Optimizing metformin to 2,000 mg/day or a maximally tolerated lower 
dose combined with emphasis on medication adherence and lifestyle can improve 
glycemia in type 2 diabetes and HbA1c values ≥6.8% (51 mmol/mol). These findings 
may help guide efforts to optimize metformin therapy among persons with type 2 
diabetes and suboptimal glycemic control.

© 2020 by the American Diabetes Association.

DOI: 10.2337/dc19-1769
PMCID: PMC7171946
PMID: 32139384 [Indexed for MEDLINE]
